References: Direct-acting oral anticoagulants for VTE prophylaxis

  • Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol 2016;3(1):e12-21. https://www.ncbi.nlm.nih.gov/pubmed/26765643
  • Clinical Excellence Commission (CEC). Non-vitamin K antagonist oral anticoagulant (NOAC) guidelines. Sydney: CEC; Updated 2017. https://www.cec.health.nsw.gov.au/keep-patients-safe/medication-safety/high-risk-medicines/anticoagulants
  • Martin KA, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost 2021. https://www.ncbi.nlm.nih.gov/pubmed/34259389
  • Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 2014;1(1):e37-46. https://www.ncbi.nlm.nih.gov/pubmed/27030066
  • Schunemann HJ, Cushman M, Burnett AE, Kahn SR, Beyer-Westendorf J, Spencer FA, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv 2018;2(22):3198-225. https://www.ncbi.nlm.nih.gov/pubmed/30482763